Stockscreener 앱 받기
0.75
2.98%
-0.023
시간 외 거래:
.75
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - PR Newswire
Oncolytics names Jared Kelly as CEO - MSN
Oncolytics Biotech stock takes off after naming new CEO - MSN
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation - PR Newswire
Oncolytics (ONCY) Names Jared Kelly as New CEO and Board Member - GuruFocus
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immu - GuruFocus
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences - GlobeNewswire
Oncolytics Biotech stock takes off after naming new CEO | 2025-06-11 | Investing News - Stockhouse
Oncolytics Biotech Inc. - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech (ONCY) Appoints New CEO, Jared Kelly - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Appoints New CEO to Drive Immunotherapy Advancements - TipRanks
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs | ONCY Stock News - GuruFocus
Oncolytics Biotech Taps $2B J&J Deal Architect as CEO, Accelerating Fast Track Cancer Programs - Stock Titan
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
(ONC) Market Dynamics and Trading Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Proactive Strategies (ONC:CA) - news.stocktradersdaily.com
Against the rise of early onset cancer: a Mugglehead roundup - Mugglehead Magazine
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
(ONC) Advanced Equity Analysis (ONC:CA) - news.stocktradersdaily.com
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings - Defense World
Stocks In Play - Baystreet.ca
Q2 EPS Forecast for Oncolytics Biotech Reduced by Analyst - Defense World
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Dow slumps 460 points, or 1.1%, in early trading following Trump's latest tariff threats targeting Europe and Apple - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - marketscreener.com
Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics (ONCY) Unveils Promising Phase I/II Clinical Trial Da - GuruFocus
Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities | ONCY Stock News - GuruFocus
Oncolytics Brief: Presenting New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - PR Newswire
HC Wainwright Issues Negative Outlook for TSE:ONC Earnings - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
ONCY: Analyst Reiterates Buy Rating with $5.00 Price Target | ONCY Stock News - GuruFocus
Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33 - Defense World
Oncolytic Virus Therapy Market Detailed In New Research Report - openPR.com
Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Options Volatility and Implied Earnings Moves Today, May 16, 2025 - The Globe and Mail
(ONC) Market Performance Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech (ONCY) Downgraded by Jones Trading | ONCY Sto - GuruFocus
Oncolytics (ONCY) Downgraded Amid CEO Search and Capital Concerns | ONCY Stock News - GuruFocus
Oncolytics Biotech’s Earnings Call: Optimism Amid Challenges - TipRanks
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Oncolytics Biotech Reports Q1 Results and Clinical Progress - TipRanks
0.39%
0.42%
자본화:
|
볼륨(24시간):